drugset

drugset / Trial / NCT00087763

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

NCT00087763 ↗

Phase 2 Completed 135 enrolled Eyetech Pharmaceuticals Pfizer · collab

RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.

Timeline

Start: 2004-03
Primary completion: —
Completion: 2006-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	pegaptanib sodium	Aptamer	—	—

Indications